Pathophysiology Quiz: Osteoporosis
20 questions · exam conditions
0:00
OsteoporosisQuestion 1 of 20

A patient with a vertebral compression fracture has a bone mineral density (BMD) T-score of -1.8, which is in the osteopenic range, not osteoporotic. How can the occurrence of a fragility fracture be explained in the context of a non-osteoporotic T-score?

The T-score is likely inaccurate due to artifact from aortic calcification, and the true BMD is much lower.
The fracture is unrelated to bone strength and was caused by excessive force that would fracture healthy bone.
BMD only measures mineral content, while fracture risk is also heavily dependent on the degradation of bone microarchitecture and quality.
The Z-score, which compares the patient to an age-matched population, is a more accurate predictor of fracture risk than the T-score.
← Back to quizzes

Pathophysiology Quiz

Pathophysiology Quiz: Osteoporosis

Practice Osteoporosis in Pathophysiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Osteoporosis, giving you a quick way to practice the rules, question types, and explanations that matter most for Pathophysiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with a vertebral compression fracture has a bone mineral density (BMD) T-score of -1.8, which is in the osteopenic range, not osteoporotic. How can the occurrence of a fragility fracture be explained in the context of a non-osteoporotic T-score?

  1. The T-score is likely inaccurate due to artifact from aortic calcification, and the true BMD is much lower.
  2. The fracture is unrelated to bone strength and was caused by excessive force that would fracture healthy bone.
  3. BMD only measures mineral content, while fracture risk is also heavily dependent on the degradation of bone microarchitecture and quality. (correct answer)
  4. The Z-score, which compares the patient to an age-matched population, is a more accurate predictor of fracture risk than the T-score.
Explanation: The correct answer is C. This question tests the concept that fracture risk is not solely determined by bone mineral density (BMD). BMD, as measured by DEXA scans, is a two-dimensional measure of mineral content per area. However, bone strength is a composite of bone mass and bone quality. Bone quality includes factors like microarchitecture (trabecular connectivity, cortical thickness), turnover rates, and the properties of the collagenous matrix. A patient can have a T-score in the osteopenic range but have severely compromised microarchitecture, making their bones fragile and susceptible to fracture with minimal trauma. A, while possible, is a specific technical issue and not the fundamental pathophysiological explanation for why fractures occur at non-osteoporotic BMDs. B contradicts the premise of a 'fragility fracture,' which is defined as a fracture occurring from a fall from standing height or less, or with minimal trauma. D is incorrect. While the Z-score provides important context (especially for suspecting secondary causes), the T-score is the standard diagnostic criterion for osteoporosis and the primary BMD metric used in most fracture risk assessment tools like FRAX.

Question 2

Long-term use of proton pump inhibitors (PPIs) has been associated with an increased risk of hip fractures. Which of the following provides the most plausible pathophysiological link for this association?

  1. PPIs directly stimulate osteoclast activity through a non-gastric H+/K+ ATPase pump located on the ruffled border.
  2. By inducing profound hypochlorhydria, PPIs impair the absorption of insoluble dietary calcium salts, leading to negative calcium balance. (correct answer)
  3. PPIs inhibit the renal 1-alpha-hydroxylase enzyme, preventing the activation of vitamin D and causing secondary hyperparathyroidism.
  4. Chronic PPI use leads to hypergastrinemia, and elevated gastrin levels have been shown to directly inhibit osteoblast function.
Explanation: The correct answer is B. The most widely accepted hypothesis linking PPIs to fracture risk involves calcium absorption. Gastric acid plays an important role in ionizing and solubilizing dietary calcium, particularly calcium carbonate, making it available for absorption in the small intestine. By suppressing acid production and causing hypochlorhydria, long-term PPI use can significantly impair the absorption of this form of calcium. Over years, this can lead to a chronic negative calcium balance, which in turn stimulates PTH secretion (secondary hyperparathyroidism) and increases bone turnover and loss, ultimately increasing fracture risk. A is incorrect. While osteoclasts do use a proton pump, it is a V-type H+-ATPase, which is distinct from the H+/K+ ATPase targeted by PPIs in the stomach. C is incorrect. There is no established evidence that PPIs directly inhibit renal 1-alpha-hydroxylase. D is incorrect. While PPIs do cause hypergastrinemia, a direct, clinically significant inhibitory effect of gastrin on osteoblasts is not the primary proposed mechanism for fracture risk.

Question 3

A patient with celiac disease has developed severe osteoporosis. The malabsorption associated with their condition impairs the uptake of dietary calcium and vitamin D. What is the correct hormonal cascade that links this malabsorption to increased bone resorption?

  1. Low vitamin D → high calcitonin → decreased osteoclast activity → impaired remodeling.
  2. Low calcium → low PTH → increased osteoblast activity → deposition of unmineralized osteoid.
  3. Low vitamin D → low calcitriol → decreased calcium absorption → hypocalcemia → elevated PTH → increased bone resorption. (correct answer)
  4. Low calcium → high estrogen → suppression of RANKL → decreased bone resorption.
Explanation: The correct answer is C. This option correctly outlines the pathophysiological sequence of secondary hyperparathyroidism. Malabsorption of vitamin D prevents its conversion to the active form, calcitriol. Calcitriol is necessary for efficient intestinal absorption of calcium. The resulting decrease in calcium absorption leads to hypocalcemia (low serum calcium). The parathyroid glands sense the low calcium and respond by increasing the secretion of parathyroid hormone (PTH). PTH acts to restore normal serum calcium levels, in part by stimulating osteoclast-mediated bone resorption to release calcium from the skeleton, which leads to osteoporosis over time. A is incorrect. Low vitamin D does not lead to high calcitonin; calcitonin is released in response to high, not low, serum calcium. B is incorrect. Low calcium stimulates, not suppresses, PTH secretion. D is incorrect. There is no physiological link between low calcium and high estrogen.

Question 4

A patient is immobilized in a full-leg cast for 12 weeks following a complex tibial fracture. DEXA scanning of the contralateral, uninjured leg shows no change, but the femoral neck on the immobilized side shows a significant decrease in BMD. This localized bone loss is best explained by:

  1. A systemic surge in cortisol due to the stress of the injury, causing generalized bone resorption.
  2. Disruption of the nutrient artery to the femur on the injured side, leading to bone ischemia and necrosis.
  3. Local changes in bone remodeling due to the absence of mechanical strain, mediated by osteocyte signaling. (correct answer)
  4. Shunting of calcium and phosphate to the healing fracture site, depleting mineral from the adjacent uninjured bone.
Explanation: The correct answer is C. This is a classic example of disuse osteoporosis. The primary mechanism is local, not systemic. Osteocytes act as mechanosensors. The absence of mechanical loading on the immobilized limb leads to changes in osteocyte signaling (e.g., increased sclerostin expression), which suppresses local bone formation by osteoblasts and increases local bone resorption by osteoclasts. The fact that the contralateral leg is unaffected confirms that this is a local phenomenon driven by the lack of mechanical strain, not a systemic hormonal change. A is incorrect because a systemic cortisol surge would be expected to affect both limbs, not just the immobilized one. B is incorrect. While a severe injury could compromise blood supply, simple immobilization does not disrupt the nutrient artery, and the resulting bone loss is a remodeling phenomenon, not necrosis. D is incorrect. While fracture healing requires minerals, the body does not actively deplete adjacent bone to supply them; it draws from systemic circulation, which is tightly regulated by hormones like PTH.

Question 5

A 58-year-old male with severe rheumatoid arthritis has been on high-dose prednisone (a glucocorticoid) for the past three years. He presents with acute back pain after lifting a bag of groceries, and imaging reveals a vertebral compression fracture.

In this patient, what is the most significant dual-action mechanism by which long-term glucocorticoid therapy increased his fracture risk?

  1. Inhibition of calcitonin secretion and potentiation of parathyroid hormone (PTH) effects on bone.
  2. Decreased intestinal calcium absorption and increased renal calcium excretion.
  3. Induction of osteoclast apoptosis and stimulation of osteoblast proliferation.
  4. Suppression of osteoblast function and promotion of osteoclast survival and activity. (correct answer)
Explanation: The correct answer is D. Glucocorticoids have a profound and multifactorial negative impact on bone health, but their most significant mechanism is a dual defect: they directly inhibit osteoblast differentiation and function while also inducing their apoptosis (programmed cell death), which severely impairs bone formation. Concurrently, they promote bone resorption by increasing the expression of RANKL and decreasing OPG, which enhances the formation, differentiation, and survival of osteoclasts. This combination of suppressed formation and enhanced resorption rapidly decreases bone mass and degrades microarchitecture. A is incorrect. While glucocorticoids can interact with the PTH axis, their primary effect is not through calcitonin or direct potentiation of PTH. B is a correct statement about glucocorticoid effects but is not the most significant direct mechanism of bone loss. These calcium-wasting effects contribute, often leading to secondary hyperparathyroidism, but the direct actions on bone cells described in D are central to the pathology. C is the opposite of what occurs. Glucocorticoids induce osteoblast apoptosis and promote osteoclast survival, not the other way around.

Question 6

A patient with chronic kidney disease (CKD) develops renal osteodystrophy, a complex bone disorder that includes features of secondary hyperparathyroidism and osteoporosis. A key initiating event in this process is the failing kidney's inability to perform which function?

  1. Synthesize osteoprotegerin (OPG), leading to unchecked osteoclast activation.
  2. Reabsorb filtered calcium, leading to profound and persistent hypocalcemia.
  3. Excrete phosphate, leading to hyperphosphatemia which complexes with calcium and stimulates FGF-23. (correct answer)
  4. Metabolize PTH into its inactive fragments, leading to prolonged PTH activity.
Explanation: The correct answer is C. The pathophysiology of renal osteodystrophy is initiated early in CKD by phosphate retention. As the glomerular filtration rate (GFR) declines, the kidneys are unable to excrete the dietary phosphate load, leading to hyperphosphatemia. This excess phosphate directly stimulates the parathyroid glands to secrete PTH. Additionally, hyperphosphatemia complexes with serum calcium, lowering ionized calcium levels, which further stimulates PTH. It also stimulates osteocytes to secrete Fibroblast Growth Factor 23 (FGF-23), which inhibits the 1-alpha-hydroxylase enzyme, thus reducing calcitriol production and further worsening calcium absorption and stimulating PTH. This cascade of events is central to the development of high-turnover bone disease seen in CKD. A is incorrect. OPG is produced primarily by osteoblasts, not the kidneys. B is incorrect. While calcium handling is deranged, phosphate retention is the more critical initiating event. D is incorrect. While the kidney is involved in PTH clearance, this is a later consequence and not the initiating step compared to phosphate retention.

Question 7

Which of the following represents a key pathophysiological distinction between typical postmenopausal osteoporosis (e.g., in a 60-year-old female) and senile osteoporosis (e.g., in an 88-year-old male)?

  1. Postmenopausal osteoporosis is a high-turnover state with elevated resorption, while senile osteoporosis is primarily a low-turnover state with impaired formation. (correct answer)
  2. Senile osteoporosis is characterized by loss of cortical bone, whereas postmenopausal osteoporosis exclusively affects trabecular bone.
  3. The primary hormonal driver in postmenopausal osteoporosis is PTH excess, while in senile osteoporosis it is estrogen deficiency.
  4. Fracture risk in senile osteoporosis is entirely dependent on T-score, while in postmenopausal osteoporosis it is more related to fall risk.
Explanation: The correct answer is A. This captures the essential difference in bone remodeling dynamics. Postmenopausal osteoporosis, driven by estrogen loss, is characterized by a high-turnover state where osteoclast-mediated resorption far outpaces bone formation. Senile osteoporosis, which affects both elderly men and women, is more complex but is centrally characterized by a progressive, age-related decline in osteoblast number and function. This leads to a low-turnover state where bone formation is insufficient to keep up with even normal levels of resorption. B is incorrect. Both types of osteoporosis affect both cortical and trabecular bone, though postmenopausal osteoporosis has a more pronounced early effect on trabecular bone due to its higher surface area and turnover rate. C has the hormonal drivers reversed. Estrogen deficiency is the hallmark of postmenopausal osteoporosis. Secondary hyperparathyroidism (due to factors like vitamin D deficiency and decreased renal function) is a common contributor to senile osteoporosis. D is incorrect. Fracture risk is multifactorial in both conditions, involving both bone density (measured by T-score) and other factors like bone quality and fall risk.

Question 8

The Wnt/β-catenin signaling pathway is crucial for osteoblastogenesis. Sclerostin, an osteocyte-derived protein, is a key negative regulator of this pathway. A loss-of-function mutation in the sclerostin gene (SOST) would be expected to result in what phenotype?

  1. Osteomalacia, with accumulation of unmineralized osteoid, due to defective matrix production.
  2. A severe, early-onset osteoporosis, due to impaired osteoblast-osteoclast coupling.
  3. Osteopetrosis, characterized by dense but brittle bone, due to complete cessation of osteoclast function.
  4. A high bone mass phenotype with decreased fracture risk, due to uninhibited bone formation. (correct answer)
Explanation: When you encounter questions about bone signaling pathways, focus on understanding the regulatory mechanisms and their downstream effects on bone formation versus resorption. The Wnt/β-catenin pathway is essential for osteoblast differentiation and bone formation. Sclerostin acts as a brake on this pathway by binding to LRP5/6 receptors and preventing Wnt signaling. When sclerostin is present, it inhibits osteoblast activity and reduces bone formation. Therefore, a loss-of-function mutation in the SOST gene (which encodes sclerostin) would remove this inhibition, leading to enhanced Wnt signaling and increased osteoblast activity. This uninhibited bone formation results in a high bone mass phenotype with stronger, denser bones and decreased fracture risk, making D correct. This matches the clinical presentation seen in sclerosteosis, a rare condition caused by SOST mutations. Option A is incorrect because sclerostin deficiency doesn't affect matrix mineralization—it affects the amount of matrix produced. Option B misrepresents the outcome; loss of sclerostin inhibition actually increases bone formation rather than causing osteoporosis. The osteoblast-osteoclast coupling remains functional. Option C describes osteopetrosis caused by osteoclast dysfunction, but sclerostin primarily regulates osteoblasts, not osteoclasts. While bone density increases, osteoclast function remains normal. Remember that in bone physiology questions, identify whether the factor in question promotes or inhibits bone formation/resorption, then trace through what happens when that factor is removed or enhanced. Loss-of-function mutations eliminate the protein's normal effect.

Question 9

A 68-year-old male is diagnosed with primary hyperparathyroidism due to a parathyroid adenoma. How does the chronic excess of parathyroid hormone (PTH) in this condition lead to an increased risk of fractures?

  1. By directly inhibiting osteoblast activity, leading to a severe reduction in bone formation.
  2. By increasing renal phosphate excretion, which causes phosphate to be leached from the bone matrix.
  3. By stimulating osteoblasts to increase their expression of RANKL, leading to increased osteoclast-mediated bone resorption. (correct answer)
  4. By promoting the conversion of vitamin D to its inactive form, thereby reducing intestinal calcium absorption.
Explanation: The correct answer is C. In a state of chronic excess, such as primary hyperparathyroidism, PTH primarily exerts catabolic effects on the skeleton. PTH receptors are located on osteoblasts, not osteoclasts. When PTH binds to osteoblasts, it stimulates them to increase their expression of RANKL and decrease their expression of OPG. The increased RANKL/OPG ratio drives the differentiation and activation of osteoclasts, leading to increased bone resorption and release of calcium into the bloodstream. This chronic resorption, particularly of cortical bone, weakens the skeleton and increases fracture risk. A is incorrect; while PTH can have complex effects, its primary catabolic action is not direct inhibition of osteoblasts. In fact, intermittent PTH exposure is anabolic. B is incorrect. PTH does increase renal phosphate excretion, but this does not cause phosphate to be leached from bone. The bone resorption is an active, cell-mediated process to liberate calcium and phosphate together. D is incorrect. PTH does the opposite; it stimulates the kidneys (via 1-alpha-hydroxylase) to convert calcidiol (25-hydroxyvitamin D) into calcitriol (1,25-dihydroxyvitamin D), the active form of vitamin D, which then increases intestinal calcium absorption.

Question 10

An 80-year-old female presents with a hip fracture after a simple fall. She has a T-score of -3.2. Which of the following age-related physiological changes is LEAST likely to have been a major contributor to her high fracture risk?

  1. Accumulation of advanced glycation end-products (AGEs) in bone collagen, making the matrix more brittle.
  2. A significant increase in osteoprotegerin (OPG) production by senescent osteoblasts. (correct answer)
  3. A decline in the number and functional capacity of osteoblast precursor cells in the bone marrow.
  4. Reduced physical activity and sarcopenia leading to both decreased mechanical loading and increased fall risk.
Explanation: The correct answer is B. An increase in OPG production would be protective against bone loss, as OPG is a decoy receptor that inhibits RANKL and thus suppresses osteoclast formation and activity. In reality, the RANKL/OPG ratio tends to increase with age, favoring resorption. Therefore, an increase in OPG is the least likely contributor to her condition. A is a key aspect of declining bone quality with age. AGEs cross-link collagen fibers, reducing the bone's flexibility and toughness. C is a hallmark of senile osteoporosis. The regenerative capacity of the osteoblast lineage declines with age, impairing bone formation. D is a critical factor in fractures in the elderly. Sarcopenia (age-related muscle loss) and reduced activity lead to less mechanical stimulation for bone (disuse) and also make falls more likely and more impactful.

Question 11

Which of the following represents a key pathophysiological distinction between typical postmenopausal osteoporosis (e.g., in a 60-year-old female) and senile osteoporosis (e.g., in an 88-year-old male)?

  1. Postmenopausal osteoporosis is a high-turnover state with elevated resorption, while senile osteoporosis is primarily a low-turnover state with impaired formation. (correct answer)
  2. Senile osteoporosis is characterized by loss of cortical bone, whereas postmenopausal osteoporosis exclusively affects trabecular bone.
  3. The primary hormonal driver in postmenopausal osteoporosis is PTH excess, while in senile osteoporosis it is estrogen deficiency.
  4. Fracture risk in senile osteoporosis is entirely dependent on T-score, while in postmenopausal osteoporosis it is more related to fall risk.
Explanation: The correct answer is A. This captures the essential difference in bone remodeling dynamics. Postmenopausal osteoporosis, driven by estrogen loss, is characterized by a high-turnover state where osteoclast-mediated resorption far outpaces bone formation. Senile osteoporosis, which affects both elderly men and women, is more complex but is centrally characterized by a progressive, age-related decline in osteoblast number and function. This leads to a low-turnover state where bone formation is insufficient to keep up with even normal levels of resorption. B is incorrect. Both types of osteoporosis affect both cortical and trabecular bone, though postmenopausal osteoporosis has a more pronounced early effect on trabecular bone due to its higher surface area and turnover rate. C has the hormonal drivers reversed. Estrogen deficiency is the hallmark of postmenopausal osteoporosis. Secondary hyperparathyroidism (due to factors like vitamin D deficiency and decreased renal function) is a common contributor to senile osteoporosis. D is incorrect. Fracture risk is multifactorial in both conditions, involving both bone density (measured by T-score) and other factors like bone quality and fall risk.

Question 12

A 68-year-old male is diagnosed with primary hyperparathyroidism due to a parathyroid adenoma. How does the chronic excess of parathyroid hormone (PTH) in this condition lead to an increased risk of fractures?

  1. By directly inhibiting osteoblast activity, leading to a severe reduction in bone formation.
  2. By increasing renal phosphate excretion, which causes phosphate to be leached from the bone matrix.
  3. By stimulating osteoblasts to increase their expression of RANKL, leading to increased osteoclast-mediated bone resorption. (correct answer)
  4. By promoting the conversion of vitamin D to its inactive form, thereby reducing intestinal calcium absorption.
Explanation: The correct answer is C. In a state of chronic excess, such as primary hyperparathyroidism, PTH primarily exerts catabolic effects on the skeleton. PTH receptors are located on osteoblasts, not osteoclasts. When PTH binds to osteoblasts, it stimulates them to increase their expression of RANKL and decrease their expression of OPG. The increased RANKL/OPG ratio drives the differentiation and activation of osteoclasts, leading to increased bone resorption and release of calcium into the bloodstream. This chronic resorption, particularly of cortical bone, weakens the skeleton and increases fracture risk. A is incorrect; while PTH can have complex effects, its primary catabolic action is not direct inhibition of osteoblasts. In fact, intermittent PTH exposure is anabolic. B is incorrect. PTH does increase renal phosphate excretion, but this does not cause phosphate to be leached from bone. The bone resorption is an active, cell-mediated process to liberate calcium and phosphate together. D is incorrect. PTH does the opposite; it stimulates the kidneys (via 1-alpha-hydroxylase) to convert calcidiol (25-hydroxyvitamin D) into calcitriol (1,25-dihydroxyvitamin D), the active form of vitamin D, which then increases intestinal calcium absorption.

Question 13

Bisphosphonates are a common class of drugs used to treat osteoporosis. Their mechanism involves binding to hydroxyapatite in bone and being internalized by osteoclasts. Which of the following describes the key intracellular effect of nitrogen-containing bisphosphonates that leads to reduced bone resorption?

  1. They activate the RANK receptor on osteoclasts, mimicking OPG and causing competitive inhibition.
  2. They inhibit farnesyl pyrophosphate synthase, disrupting a pathway essential for maintaining the osteoclast's cytoskeleton and ruffled border. (correct answer)
  3. They directly chelate intracellular calcium within the osteoclast, preventing the exocytosis of acidic vesicles.
  4. They upregulate the expression of calcitonin receptors on the osteoclast surface, making them more sensitive to endogenous calcitonin.
Explanation: The correct answer is B. This question tests the mechanism of a key osteoporosis treatment to assess understanding of osteoclast biology. Nitrogen-containing bisphosphonates (e.g., alendronate, risedronate) work by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway. This inhibition prevents the synthesis of isoprenoid lipids (like farnesyl pyrophosphate and geranylgeranyl pyrophosphate) that are required for the post-translational modification (prenylation) of small GTP-binding proteins (e.g., Ras, Rho). These proteins are essential for osteoclast function, including the maintenance of the ruffled border, cytoskeletal arrangement, and cell survival. Disruption of this process leads to osteoclast inactivation and apoptosis, thus reducing bone resorption. A is incorrect. Bisphosphonates do not interact with the RANK receptor. C is incorrect. Their primary mechanism is not calcium chelation. D is incorrect. They do not affect calcitonin receptor expression.

Question 14

Intermittent, low-dose administration of teriparatide, a recombinant human PTH analogue, is an anabolic therapy for osteoporosis that increases bone mass. This is paradoxical, as chronic high levels of PTH cause bone loss. What is the cellular basis for this anabolic effect?

  1. Intermittent PTH preferentially stimulates osteoblast proliferation and differentiation while allowing time for subsequent mineralization between doses. (correct answer)
  2. Intermittent PTH causes a rapid and sustained decrease in sclerostin levels, permanently activating the Wnt pathway.
  3. Low doses of PTH exclusively stimulate OPG production without affecting RANKL expression, thereby blocking resorption.
  4. Pulsatile PTH administration enhances the direct binding of PTH to osteoclasts, marking them for apoptosis.
Explanation: The correct answer is A. The differential effect of PTH is dose- and time-dependent. While continuous high levels of PTH lead to a net catabolic effect (more resorption than formation), intermittent administration (e.g., once-daily injection) has a net anabolic effect. This is because the brief pulse of PTH preferentially stimulates osteoblast proliferation and differentiation and inhibits their apoptosis. This initial anabolic 'window' of bone formation occurs before the subsequent, slower stimulation of RANKL and osteoclast-mediated resorption. The time between doses allows for the new bone matrix to be laid down and mineralized, leading to a net gain in bone mass over time. B is incorrect. While PTH does influence sclerostin, the effect is not permanent. C is incorrect. PTH stimulates both RANKL and OPG; the anabolic effect comes from the timing and magnitude of the osteoblast response preceding the osteoclast response. D is incorrect. PTH does not bind directly to osteoclasts; its effects are mediated through osteoblasts.

Question 15

Long-term use of proton pump inhibitors (PPIs) has been associated with an increased risk of hip fractures. Which of the following provides the most plausible pathophysiological link for this association?

  1. PPIs directly stimulate osteoclast activity through a non-gastric H+/K+ ATPase pump located on the ruffled border.
  2. By inducing profound hypochlorhydria, PPIs impair the absorption of insoluble dietary calcium salts, leading to negative calcium balance. (correct answer)
  3. PPIs inhibit the renal 1-alpha-hydroxylase enzyme, preventing the activation of vitamin D and causing secondary hyperparathyroidism.
  4. Chronic PPI use leads to hypergastrinemia, and elevated gastrin levels have been shown to directly inhibit osteoblast function.
Explanation: The correct answer is B. The most widely accepted hypothesis linking PPIs to fracture risk involves calcium absorption. Gastric acid plays an important role in ionizing and solubilizing dietary calcium, particularly calcium carbonate, making it available for absorption in the small intestine. By suppressing acid production and causing hypochlorhydria, long-term PPI use can significantly impair the absorption of this form of calcium. Over years, this can lead to a chronic negative calcium balance, which in turn stimulates PTH secretion (secondary hyperparathyroidism) and increases bone turnover and loss, ultimately increasing fracture risk. A is incorrect. While osteoclasts do use a proton pump, it is a V-type H+-ATPase, which is distinct from the H+/K+ ATPase targeted by PPIs in the stomach. C is incorrect. There is no established evidence that PPIs directly inhibit renal 1-alpha-hydroxylase. D is incorrect. While PPIs do cause hypergastrinemia, a direct, clinically significant inhibitory effect of gastrin on osteoblasts is not the primary proposed mechanism for fracture risk.

Question 16

A patient is immobilized in a full-leg cast for 12 weeks following a complex tibial fracture. DEXA scanning of the contralateral, uninjured leg shows no change, but the femoral neck on the immobilized side shows a significant decrease in BMD. This localized bone loss is best explained by:

  1. A systemic surge in cortisol due to the stress of the injury, causing generalized bone resorption.
  2. Disruption of the nutrient artery to the femur on the injured side, leading to bone ischemia and necrosis.
  3. Local changes in bone remodeling due to the absence of mechanical strain, mediated by osteocyte signaling. (correct answer)
  4. Shunting of calcium and phosphate to the healing fracture site, depleting mineral from the adjacent uninjured bone.
Explanation: The correct answer is C. This is a classic example of disuse osteoporosis. The primary mechanism is local, not systemic. Osteocytes act as mechanosensors. The absence of mechanical loading on the immobilized limb leads to changes in osteocyte signaling (e.g., increased sclerostin expression), which suppresses local bone formation by osteoblasts and increases local bone resorption by osteoclasts. The fact that the contralateral leg is unaffected confirms that this is a local phenomenon driven by the lack of mechanical strain, not a systemic hormonal change. A is incorrect because a systemic cortisol surge would be expected to affect both limbs, not just the immobilized one. B is incorrect. While a severe injury could compromise blood supply, simple immobilization does not disrupt the nutrient artery, and the resulting bone loss is a remodeling phenomenon, not necrosis. D is incorrect. While fracture healing requires minerals, the body does not actively deplete adjacent bone to supply them; it draws from systemic circulation, which is tightly regulated by hormones like PTH.

Question 17

The Wnt/β-catenin signaling pathway is crucial for osteoblastogenesis. Sclerostin, an osteocyte-derived protein, is a key negative regulator of this pathway. A loss-of-function mutation in the sclerostin gene (SOST) would be expected to result in what phenotype?

  1. Osteomalacia, with accumulation of unmineralized osteoid, due to defective matrix production.
  2. A severe, early-onset osteoporosis, due to impaired osteoblast-osteoclast coupling.
  3. Osteopetrosis, characterized by dense but brittle bone, due to complete cessation of osteoclast function.
  4. A high bone mass phenotype with decreased fracture risk, due to uninhibited bone formation. (correct answer)
Explanation: When you encounter questions about bone signaling pathways, focus on understanding the regulatory mechanisms and their downstream effects on bone formation versus resorption. The Wnt/β-catenin pathway is essential for osteoblast differentiation and bone formation. Sclerostin acts as a brake on this pathway by binding to LRP5/6 receptors and preventing Wnt signaling. When sclerostin is present, it inhibits osteoblast activity and reduces bone formation. Therefore, a loss-of-function mutation in the SOST gene (which encodes sclerostin) would remove this inhibition, leading to enhanced Wnt signaling and increased osteoblast activity. This uninhibited bone formation results in a high bone mass phenotype with stronger, denser bones and decreased fracture risk, making D correct. This matches the clinical presentation seen in sclerosteosis, a rare condition caused by SOST mutations. Option A is incorrect because sclerostin deficiency doesn't affect matrix mineralization—it affects the amount of matrix produced. Option B misrepresents the outcome; loss of sclerostin inhibition actually increases bone formation rather than causing osteoporosis. The osteoblast-osteoclast coupling remains functional. Option C describes osteopetrosis caused by osteoclast dysfunction, but sclerostin primarily regulates osteoblasts, not osteoclasts. While bone density increases, osteoclast function remains normal. Remember that in bone physiology questions, identify whether the factor in question promotes or inhibits bone formation/resorption, then trace through what happens when that factor is removed or enhanced. Loss-of-function mutations eliminate the protein's normal effect.

Question 18

A 70-year-old female with osteoporosis is noted to have lost 2 inches in height over the past 5 years and has developed a mild thoracic kyphosis. These findings are most likely the direct result of which type of fracture?

  1. A subcapital fracture of the humerus with impaction.
  2. Bilateral, non-displaced fractures of the femoral necks.
  3. Pathologic fractures of the ribs at the costovertebral joints.
  4. Multiple, often asymptomatic, vertebral compression fractures. (correct answer)
Explanation: When you encounter a pathophysiology question about height loss and spinal deformity in an elderly osteoporotic patient, think about which fractures would directly affect spinal structure and posture. The combination of progressive height loss (2 inches over 5 years) and developing thoracic kyphosis ("dowager's hump") is the classic presentation of vertebral compression fractures. In osteoporosis, weakened vertebral bodies gradually collapse under normal weight-bearing stress, often without causing acute pain. As multiple vertebrae compress, the spine loses its normal curvature, creating the characteristic forward-hunched posture and measurable height reduction. This process typically occurs gradually and may go unnoticed until the deformity becomes apparent. Option A, a subcapital humeral fracture, affects the shoulder region and wouldn't impact spinal alignment or height. Option B, bilateral femoral neck fractures, would cause severe hip pain and mobility issues but wouldn't directly alter spinal curvature or standing height. Option C, rib fractures at costovertebral joints, might cause chest pain but wouldn't produce the progressive postural changes or significant height loss described. The key distinguishing feature is that vertebral compression fractures are often "silent" - they develop gradually without dramatic symptoms, unlike the acute pain you'd expect from hip or shoulder fractures. The cumulative effect of multiple compressed vertebrae creates the measurable height loss and characteristic spinal deformity. Remember: When you see height loss plus spinal deformity in osteoporosis, think vertebral compression fractures. This is one of the most common and clinically significant complications of osteoporosis in elderly patients.

Question 19

How does chronic systemic inflammation, such as that seen in untreated rheumatoid arthritis, contribute to the development of both localized periarticular osteoporosis and generalized systemic osteoporosis?

  1. Inflammatory cytokines like TNF-α and IL-6 directly suppress osteoblast function and promote osteoclastogenesis by upregulating RANKL expression. (correct answer)
  2. Systemic inflammation triggers a compensatory increase in calcitonin, which impairs the normal bone remodeling process and leads to brittle bone.
  3. Pro-inflammatory mediators cause a downregulation of PTH receptors on osteoblasts, uncoupling bone formation from resorption.
  4. Chronic inflammation enhances intestinal calcium absorption and renal calcium retention, leading to hypercalcemia and disuse bone atrophy.
Explanation: The correct answer is A. Chronic inflammation is a significant risk factor for osteoporosis. Pro-inflammatory cytokines, particularly Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), play a central role. These cytokines have direct effects on bone cells. They stimulate the expression of RANKL by osteoblasts and synovial cells while inhibiting OPG. This strongly promotes the differentiation and activity of osteoclasts, leading to bone resorption. They also directly inhibit osteoblast differentiation and function, impairing bone formation. This dual effect results in localized bone loss around inflamed joints and also contributes to systemic bone loss. B is incorrect. Inflammation does not increase calcitonin. C is incorrect. While uncoupling occurs, the mechanism is not downregulation of PTH receptors. D is incorrect. Chronic inflammation is associated with bone loss, not hypercalcemia from enhanced calcium absorption; in fact, it can contribute to the 'anemia of chronic disease' and general cachexia.

Question 20

A 58-year-old male with severe rheumatoid arthritis has been on high-dose prednisone (a glucocorticoid) for the past three years. He presents with acute back pain after lifting a bag of groceries, and imaging reveals a vertebral compression fracture.

In this patient, what is the most significant dual-action mechanism by which long-term glucocorticoid therapy increased his fracture risk?

  1. Inhibition of calcitonin secretion and potentiation of parathyroid hormone (PTH) effects on bone.
  2. Decreased intestinal calcium absorption and increased renal calcium excretion.
  3. Induction of osteoclast apoptosis and stimulation of osteoblast proliferation.
  4. Suppression of osteoblast function and promotion of osteoclast survival and activity. (correct answer)
Explanation: The correct answer is D. Glucocorticoids have a profound and multifactorial negative impact on bone health, but their most significant mechanism is a dual defect: they directly inhibit osteoblast differentiation and function while also inducing their apoptosis (programmed cell death), which severely impairs bone formation. Concurrently, they promote bone resorption by increasing the expression of RANKL and decreasing OPG, which enhances the formation, differentiation, and survival of osteoclasts. This combination of suppressed formation and enhanced resorption rapidly decreases bone mass and degrades microarchitecture. A is incorrect. While glucocorticoids can interact with the PTH axis, their primary effect is not through calcitonin or direct potentiation of PTH. B is a correct statement about glucocorticoid effects but is not the most significant direct mechanism of bone loss. These calcium-wasting effects contribute, often leading to secondary hyperparathyroidism, but the direct actions on bone cells described in D are central to the pathology. C is the opposite of what occurs. Glucocorticoids induce osteoblast apoptosis and promote osteoclast survival, not the other way around.